Jci_page_head_homepage_01 Jci_page_head_homepage_02
David L. Boone, Averil Ma
Published in Volume 111, Issue 9
J Clin Invest. 2003; 111(9):1284–1286 doi:10.1172/JCI18545
Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

Model illustrating the roles of the Toll-like receptor (TLR) and Stat3 in IBD. Myeloid cells respond to LPS-mediated TLR stimulation. Normally, inflammation is controlled by IL-10, which stimulates myeloid cell Stat3 activation to suppress TLR-induced IL-12/IL-23 production (a). Kobayashi et al. (7) demonstrate that in LysMCre/Stat3flox– mice, IL-10 does not effectively suppress IL-12/IL-23 production. IL-12/IL-23 release activates lymphocytes, causing an exaggerated bias toward Th1-type inflammation (b).